About this Research Topic
We welcome Original Research articles, Methods, Reviews, Perspectives and Opinions using -omics technologies to study the human immune system, including (but not limited to) these topics:
• Specific immune cell populations and/or subsets (e.g. T cells, memory B cells, myeloid precursors…) under healthy and/or disease conditions.
• Cell-cell interactions between different immune cells (e.g. innate and adaptive immune cells) and also between immune cells and tissues (e.g. lymph nodes, skin, spleen).
• Cross-talk between immune and cancer cells.
• Immunotherapy.
• Bioinformatics integration methods of multi-omics data for immunity knowledge.
• Identification of specific markers of immune cell populations by different omics.
• Strategies for biological interpretation and visualization of multi-omics data.
• Novel -omic applications in the study of disorders of the immune system.
Prof. Jacques J.M. van Dongen, MD, PhD, is chairman of the EuroFlow consortium and the ESLHO foundation and is one of the inventors on EuroFlow-owned intellectual property. The related patents are licensed to Cytognos (Salamanca, ES) and BD Biosciences (San José, CA), which companies pay royalties to the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. J.J.M. van Dongen reports an Educational Services Agreement from BD Biosciences and a Scientific Advisory Agreement from Cytognos; all related fees and honoraria are for the Department of Immunology at Leiden University Medical Center.
Keywords: multi-omics, immune system, disease, proteomics, transcriptomics, single-cell, cell-cell interaction, immune tissues (structures), big data
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.